Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84


Identification of c.1531C>T Pathogenic Variant in the CDH1 Gene as a Novel Germline Mutation of Hereditary Diffuse Gastric Cancer.

Norero E, Alarcon MA, Hakkaart C, de Mayo T, Mellado C, Garrido M, Aguayo G, Lagos M, Torres J, Calvo A, Guilford P, Corvalan AH.

Int J Mol Sci. 2019 Oct 9;20(20). pii: E4980. doi: 10.3390/ijms20204980.


Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.

Bougen-Zhukov N, Nouri Y, Godwin T, Taylor M, Hakkaart C, Single A, Brew T, Permina E, Chen A, Black MA, Guilford P.

Cancers (Basel). 2019 Sep 13;11(9). pii: E1359. doi: 10.3390/cancers11091359.


A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.

Beetham H, Chen A, Telford BJ, Single A, Jarman KE, Lackovic K, Luxenburger A, Guilford P.

Sci Rep. 2019 Aug 29;9(1):12511. doi: 10.1038/s41598-019-48929-0.


Comparison of Roche Cell-Free DNA collection Tubes ® to Streck Cell-Free DNA BCT ® s for sample stability using healthy volunteers.

Parackal S, Zou D, Day R, Black M, Guilford P.

Pract Lab Med. 2019 Jun 18;16:e00125. doi: 10.1016/j.plabm.2019.e00125. eCollection 2019 Aug.


Hereditary gastric cancer: what's new? Update 2013-2018.

van der Post RS, Oliveira C, Guilford P, Carneiro F.

Fam Cancer. 2019 Jul;18(3):363-367. doi: 10.1007/s10689-019-00127-7. Review.


Clinical spectrum and pleiotropic nature of CDH1 germline mutations.

Figueiredo J, Melo S, Carneiro P, Moreira AM, Fernandes MS, Ribeiro AS, Guilford P, Paredes J, Seruca R.

J Med Genet. 2019 Apr;56(4):199-208. doi: 10.1136/jmedgenet-2018-105807. Epub 2019 Jan 19.


E-cadherin signal sequence disruption: a novel mechanism underlying hereditary cancer.

Figueiredo J, Melo S, Gamet K, Godwin T, Seixas S, Sanches JM, Guilford P, Seruca R.

Mol Cancer. 2018 Aug 1;17(1):112. doi: 10.1186/s12943-018-0859-0.


E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.

Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ.

Gastric Cancer. 2019 Mar;22(2):273-286. doi: 10.1007/s10120-018-0859-1. Epub 2018 Jul 31.


Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori.

Hakkaart C, Ellison-Loschmann L, Day R, Sporle A, Koea J, Harawira P, Cheng S, Gray M, Whaanga T, Pearce N, Guilford P.

Fam Cancer. 2019 Jan;18(1):83-90. doi: 10.1007/s10689-018-0080-8.


Risk of stomach cancer in Aotearoa/New Zealand: A Māori population based case-control study.

Ellison-Loschmann L, Sporle A, Corbin M, Cheng S, Harawira P, Gray M, Whaanga T, Guilford P, Koea J, Pearce N.

PLoS One. 2017 Jul 21;12(7):e0181581. doi: 10.1371/journal.pone.0181581. eCollection 2017.


Where to from here? Posthumous healthcare data, digital e(lectronic)-mortality and New Zealand's healthcare future.

Hoeksema K, Wee R, Macdonald A, Guilford P, Wall J, Cornwall J.

N Z Med J. 2017 Jul 21;130(1459):64-70.


Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.

Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H, Scherr D, Asroff S, Goldfischer E, Thill J, Darling D.

Urol Oncol. 2017 Aug;35(8):531.e15-531.e22. doi: 10.1016/j.urolonc.2017.03.008. Epub 2017 Mar 31.


Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.

McInnes T, Zou D, Rao DS, Munro FM, Phillips VL, McCall JL, Black MA, Reeve AE, Guilford PJ.

BMC Cancer. 2017 Mar 28;17(1):228. doi: 10.1186/s12885-017-3226-4.


Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.

Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, Shariat SF, Lotan Y.

J Urol. 2017 Jun;197(6):1419-1426. doi: 10.1016/j.juro.2016.12.010. Epub 2016 Dec 14.


Intrinsic motivation: an overlooked component for student success.

Augustyniak RA, Ables AZ, Guilford P, Lujan HL, Cortright RN, DiCarlo SE.

Adv Physiol Educ. 2016 Dec;40(4):465-466. No abstract available.


A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation.

Single A, Beetham H, Telford BJ, Guilford P, Chen A.

J Biomol Screen. 2015 Dec;20(10):1286-93. doi: 10.1177/1087057115605765. Epub 2015 Sep 17.


Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DG.

JAMA Oncol. 2015 Apr;1(1):23-32. doi: 10.1001/jamaoncol.2014.168. Erratum in: JAMA Oncol. 2015 Apr;1(1):110.


Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers.

van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC.

J Med Genet. 2015 Jun;52(6):361-74. doi: 10.1136/jmedgenet-2015-103094. Epub 2015 May 15. Review.


Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.

Telford BJ, Chen A, Beetham H, Frick J, Brew TP, Gould CM, Single A, Godwin T, Simpson KJ, Guilford P.

Mol Cancer Ther. 2015 May;14(5):1213-23. doi: 10.1158/1535-7163.MCT-14-1092. Epub 2015 Mar 16.


E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition.

Chen A, Beetham H, Black MA, Priya R, Telford BJ, Guest J, Wiggins GA, Godwin TD, Yap AS, Guilford PJ.

BMC Cancer. 2014 Jul 30;14:552. doi: 10.1186/1471-2407-14-552.


Culture, law, ethics, and social implications: Is society ready for advanced genomic medicine?

Cornwall J, Slatter T, Guilford P, Print CG, Henaghan M, Wee R.

Australas Med J. 2014 Apr 30;7(4):200-2. doi: 10.4066/AMJ.2014.2069. eCollection 2014. No abstract available.


Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation.

Willson JS, Godwin TD, Wiggins GA, Guilford PJ, McCall JL.

J Hepatol. 2013 Oct;59(4):904-7. doi: 10.1016/j.jhep.2013.05.024. Epub 2013 May 23.


Early events in cell adhesion and polarity during epithelial-mesenchymal transition.

Huang RY, Guilford P, Thiery JP.

J Cell Sci. 2012 Oct 1;125(Pt 19):4417-22. doi: 10.1242/jcs.099697. Review. No abstract available.


A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.

O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves CF, Yoon HS, Hinder V, Masters J, Kennedy-Smith A, Beaven T, Guilford PJ.

J Urol. 2012 Sep;188(3):741-7. doi: 10.1016/j.juro.2012.05.003. Epub 2012 Jul 19.


Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades.

Evans JJ, Chitcholtan K, Dann JM, Guilford P, Harris G, Lewis LK, Nagase J, Welkamp AA, Zwerus R, Sykes PH.

Gynecol Oncol. 2012 Apr;125(1):214-9. doi: 10.1016/j.ygyno.2011.12.429. Epub 2011 Dec 16.


Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.

Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C; International Gastric Cancer Linkage Consortium.

J Med Genet. 2010 Jul;47(7):436-44. doi: 10.1136/jmg.2009.074237. Erratum in: J Med Genet. 2011 Mar;48(3):216. Van Krieken, Nicola [corrected to Van Grieken, Nicola C].


Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice.

Guilford P, Humar B, Blair V.

Gastric Cancer. 2010 Mar;13(1):1-10. doi: 10.1007/s10120-009-0531-x. Epub 2010 Apr 7. Review.


Oligonucleotide array outperforms SNP array on formalin-fixed paraffin-embedded clinical samples.

Nasri S, Anjomshoaa A, Song S, Guilford P, McNoe L, Black M, Phillips V, Reeve A, Humar B.

Cancer Genet Cytogenet. 2010 Apr 1;198(1):1-6. doi: 10.1016/j.cancergencyto.2009.12.002.


The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.

Cancer Res. 2010 Feb 15;70(4):1573-84. doi: 10.1158/0008-5472.CAN-09-3237. Epub 2010 Feb 9.


Increased levels of active c-Src distinguish invasive from in situ lobular lesions.

Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, Humar B.

Breast Cancer Res. 2009;11(4):R45. doi: 10.1186/bcr2332. Epub 2009 Jul 7.


Hereditary diffuse gastric cancer: a manifestation of lost cell polarity.

Humar B, Guilford P.

Cancer Sci. 2009 Jul;100(7):1151-7. doi: 10.1111/j.1349-7006.2009.01163.x. Epub 2009 Apr 21. Review.


Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia.

Zou D, Yoon HS, Perez D, Weeks RJ, Guilford P, Humar B.

J Pathol. 2009 Jun;218(2):265-72. doi: 10.1002/path.2541.


E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man.

Humar B, Blair V, Charlton A, More H, Martin I, Guilford P.

Cancer Res. 2009 Mar 1;69(5):2050-6. doi: 10.1158/0008-5472.CAN-08-2457. Epub 2009 Feb 17.


The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.

Mai PL, Friedlander M, Tucker K, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Bonaïti-Pellié C, Heidenreich A, Albers P, Bodrogi I, Geczi L, Olah E, Daly PA, Guilford P, Fosså SD, Heimdal K, Liubchenko L, Tjulandin SA, Stoll H, Weber W, Easton DF, Dudakia D, Huddart R, Stratton MR, Einhorn L, Korde L, Nathanson KL, Bishop DT, Rapley EA, Greene MH.

Urol Oncol. 2010 Sep-Oct;28(5):492-9. doi: 10.1016/j.urolonc.2008.10.004. Epub 2009 Jan 22.


Predicting clinical outcome through molecular profiling in stage III melanoma.

John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS.

Clin Cancer Res. 2008 Aug 15;14(16):5173-80. doi: 10.1158/1078-0432.CCR-07-4170.


A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population.

Nasri S, More H, Graziano F, Ruzzo A, Wilson E, Dunbier A, McKinney C, Merriman T, Guilford P, Magnani M, Humar B.

BMC Cancer. 2008 May 15;8:138. doi: 10.1186/1471-2407-8-138.


Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.

Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, Nishiyama H, Kamoto T, Mikami Y, Tanaka Y, Jung G, Akiyama H, Nobumasa H, Guilford P, Reeve A, Okuno Y, Tsujimoto G, Nakamura E, Ogawa O.

Clin Cancer Res. 2008 May 1;14(9):2579-87. doi: 10.1158/1078-0432.CCR-07-1922.


Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer.

Humar B, Guilford P.

Future Oncol. 2008 Apr;4(2):229-39. doi: 10.2217/14796694.4.2.229. Review.


Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder.

Holyoake A, O'Sullivan P, Pollock R, Best T, Watanabe J, Kajita Y, Matsui Y, Ito M, Nishiyama H, Kerr N, da Silva Tatley F, Cambridge L, Toro T, Ogawa O, Guilford P.

Clin Cancer Res. 2008 Feb 1;14(3):742-9. doi: 10.1158/1078-0432.CCR-07-1672.


Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors.

Linger R, Dudakia D, Huddart R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Stoppa-Lyonnet D, Bonaïti-Pellié C, Heidenreich A, Albers P, Olah E, Geczi L, Bodrogi I, Daly PA, Guilford P, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Einhorn L, McMaster M, Korde L, Greene MH, Nathanson KL, Cortessis V, Easton DF, Bishop DT, Stratton MR, Rapley EA.

Genes Chromosomes Cancer. 2008 Mar;47(3):247-52.


P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.

Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford P, Reeve A, Ogawa O.

J Urol. 2007 Sep;178(3 Pt 1):1073-9. Epub 2007 Jul 20.


Expression of Krüppel-like factor 5 in human gastric carcinomas.

Kwak MK, Lee HJ, Hur K, Park DJ, Lee HS, Kim WH, Lee KU, Choe KJ, Guilford P, Yang HK.

J Cancer Res Clin Oncol. 2008 Feb;134(2):163-7. Epub 2007 Jul 11.


Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer.

Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, Guilford P.

Cancer Res. 2007 Mar 15;67(6):2480-9.


Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer.

Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, Yoon HS, McCall JL, Siewert JR, Holzmann B, Reeve AE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507.


Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models.

Matsui S, Ito M, Nishiyama H, Uno H, Kotani H, Watanabe J, Guilford P, Reeve A, Fukushima M, Ogawa O.

Bioinformatics. 2007 Mar 15;23(6):732-8. Epub 2007 Jan 18.


Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene.

More H, Humar B, Weber W, Ward R, Christian A, Lintott C, Graziano F, Ruzzo AM, Acosta E, Boman B, Harlan M, Ferreira P, Seruca R, Suriano G, Guilford P.

Hum Mutat. 2007 Feb;28(2):203.


A short guide to hereditary diffuse gastric cancer.

Guilford P, Blair V, More H, Humar B.

Hered Cancer Clin Pract. 2007 Dec 15;5(4):183-94. doi: 10.1186/1897-4287-5-4-183.


Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer.

Ramos-de la Medina A, More H, Medina-Franco H, Humar B, Gamboa A, Ortiz LJ, Donohue JH, Guilford P.

Rev Esp Enferm Dig. 2006 Jan;98(1):36-41. English, Spanish.


Hereditary diffuse gastric cancer: diagnosis and management.

Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P.

Clin Gastroenterol Hepatol. 2006 Mar;4(3):262-75. Review.


Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.

Crockford GP, Linger R, Hockley S, Dudakia D, Johnson L, Huddart R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaïti-Pellié C, Heidenreich A, Albers P, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Guilford P, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Forman D, Oliver T, Einhorn L, McMaster M, Kramer J, Greene MH, Weber BL, Nathanson KL, Cortessis V, Easton DF, Bishop DT, Stratton MR, Rapley EA.

Hum Mol Genet. 2006 Feb 1;15(3):443-51. Epub 2006 Jan 11.


Supplemental Content

Loading ...
Support Center